Compugen Ltd. (CGEN) Income Statement Analysis

See more : 1st Colonial Bancorp, Inc. (FCOB) Income Statement Analysis – Financial Results

Complete financial analysis of Compugen Ltd. (CGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Compugen Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Life Insurance Corporation of India (LICI.NS) Income Statement Analysis – Financial Results
Corning Natural Gas Holding Corporation (CNIGP) Income Statement Analysis – Financial Results
Société de Services, de Participations, de Direction et d’Elaboration Société anonyme (SPA.BR) Income Statement Analysis – Financial Results
Independent Tankers Corporation Limited (ITKSF) Income Statement Analysis – Financial Results
Donnelley Financial Solutions, Inc. (DFIN) Income Statement Analysis – Financial Results

Compugen Ltd. (CGEN)

Industry: Biotechnology

Sector: Healthcare

Website: https://cgen.com

About Compugen Ltd.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	33.46M	7.50M	6.00M	2.00M	0.00	17.80M	0.00	712.00K	9.28M	12.37M	3.55M	242.00K	-424.00K	1.12M	250.00K	338.00K	180.00K	215.00K	646.00K	4.03M	8.83M	11.10M	11.36M	6.89M	3.24M
Cost of Revenue	2.00M	975.00K	680.00K	60.00K	989.00K	1.03M	1.59M	223.00K	1.63M	3.34M	2.51M	201.00K	424.00K	224.00K	0.00	7.00K	0.00	6.00K	148.00K	1.10M	2.28M	2.82M	3.46M	478.00K	-769.00K
Gross Profit	31.46M	6.53M	5.32M	1.94M	-989.00K	16.77M	-1.59M	489.00K	7.64M	9.02M	1.04M	41.00K	-848.00K	891.00K	250.00K	331.00K	180.00K	209.00K	498.00K	2.93M	6.55M	8.28M	7.91M	6.41M	4.01M
Gross Profit Ratio	94.01%	87.00%	88.67%	97.00%	0.00%	94.19%	0.00%	68.68%	82.40%	72.96%	29.30%	16.94%	200.00%	79.91%	100.00%	97.93%	100.00%	97.21%	77.09%	72.68%	74.22%	74.60%	69.59%	93.06%	123.76%
Research & Development	34.47M	30.65M	28.69M	22.76M	19.82M	30.32M	28.58M	24.55M	21.25M	15.07M	12.28M	9.44M	6.78M	5.23M	5.05M	8.75M	8.39M	9.81M	10.47M	12.32M	13.31M	14.17M	15.98M	12.17M	6.68M
General & Administrative	9.73M	10.32M	10.86M	9.81M	8.41M	8.04M	7.63M	7.35M	6.01M	5.45M	4.85M	3.46M	4.59M	2.91M	2.15M	3.50M	0.00	0.00	0.00	3.61M	4.38M	5.40M	0.00	0.00	0.00
Selling & Marketing	244.00K	932.00K	842.00K	871.00K	651.00K	1.63M	1.19M	1.17M	1.31M	838.00K	962.00K	684.00K	610.00K	633.00K	681.00K	996.00K	0.00	0.00	0.00	5.54M	6.57M	3.78M	0.00	0.00	0.00
SG&A	9.98M	11.25M	11.70M	10.68M	9.06M	9.68M	8.82M	8.52M	7.32M	6.29M	5.81M	4.14M	5.20M	3.54M	2.83M	4.50M	4.25M	4.39M	4.91M	6.19M	7.46M	9.15M	10.95M	9.18M	4.32M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-523.00K	-811.00K	-588.00K	281.00K	0.00	0.00	0.00	0.00	0.00	0.00	2.82M	18.44M	13.89M	0.00	0.00	1.86M
Operating Expenses	44.45M	41.90M	40.39M	33.44M	28.88M	39.99M	37.41M	33.07M	28.56M	21.36M	18.08M	13.58M	11.98M	8.77M	7.88M	13.24M	12.64M	14.20M	15.38M	18.50M	20.77M	23.32M	26.92M	21.35M	12.85M
Cost & Expenses	46.45M	42.87M	41.07M	33.50M	28.88M	41.03M	37.41M	33.30M	30.20M	24.70M	20.59M	13.78M	11.98M	8.99M	7.88M	13.25M	12.64M	14.21M	15.52M	19.60M	23.04M	26.14M	30.38M	21.83M	12.09M
Interest Income	3.24M	1.74M	894.00K	1.77M	935.00K	643.00K	523.00K	728.00K	815.00K	346.00K	169.00K	301.00K	0.00	0.00	0.00	502.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	31.00K	27.00K	25.00K	42.00K	32.00K	620.00K	508.00K	705.00K	755.00K	330.00K	141.00K	240.00K	-306.00K	241.00K	65.00K	154.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	476.00K	482.00K	461.00K	715.00K	989.00K	1.39M	1.59M	1.48M	1.11M	658.00K	370.00K	299.00K	179.00K	201.00K	264.00K	477.00K	633.00K	996.00K	2.39M	1.76M	2.68M	2.90M	4.28M	4.99M	1.86M
EBITDA	-12.52M	-35.37M	-34.61M	-31.50M	-27.04M	-21.83M	-35.46M	-31.10M	-19.81M	-12.34M	-17.04M	-13.27M	-11.81M	-7.68M	-7.37M	-12.03M	-11.83M	-13.08M	-12.49M	-13.81M	-12.20M	-12.15M	-14.74M	-9.94M	-6.99M
EBITDA Ratio	-37.41%	-471.65%	-584.57%	-1,574.80%	0.00%	-130.49%	0.00%	-4,576.26%	-225.48%	-99.76%	-480.22%	-5,595.87%	2,891.51%	-767.09%	-4,566.00%	-3,835.80%	-6,578.33%	-6,095.81%	-1,967.49%	-353.89%	-138.26%	-109.45%	-126.73%	-145.13%	-215.32%
Operating Income	-12.99M	-35.37M	-35.07M	-31.50M	-28.88M	-23.23M	-37.41M	-32.58M	-20.92M	-12.34M	-17.04M	-13.54M	-11.98M	-7.88M	-7.63M	-12.91M	-12.46M	-13.99M	-14.88M	-15.58M	-14.22M	-15.04M	-19.02M	-16.18M	-8.85M
Operating Income Ratio	-38.83%	-471.65%	-584.57%	-1,574.80%	0.00%	-130.49%	0.00%	-4,576.26%	-225.48%	-99.76%	-480.22%	-5,595.87%	2,825.24%	-706.55%	-3,051.60%	-3,820.12%	-6,922.22%	-6,508.37%	-2,303.10%	-386.81%	-161.07%	-135.57%	-167.42%	-234.74%	-273.34%
Total Other Income/Expenses	3.21M	1.74M	871.00K	1.80M	820.00K	628.00K	339.00K	1.10M	1.15M	1.76M	3.46M	-86.00K	0.00	675.00K	3.79M	401.00K	1.00M	1.94M	900.00K	1.86M	2.77M	2.84M	-348.00K	1.30M	-18.00K
Income Before Tax	-9.78M	-33.64M	-34.20M	-29.70M	-28.06M	-22.60M	-37.07M	-31.49M	-19.77M	-10.73M	-13.58M	-13.63M	-12.00M	-7.44M	-3.84M	-12.51M	-11.46M	-13.88M	-14.66M	-15.14M	-13.55M	-13.40M	-19.37M	-14.87M	-8.87M
Income Before Tax Ratio	-29.24%	-448.48%	-570.05%	-1,484.90%	0.00%	-126.96%	0.00%	-4,422.19%	-213.14%	-86.80%	-382.73%	-5,631.40%	2,831.13%	-667.62%	-1,537.20%	-3,701.48%	-6,365.56%	-6,457.67%	-2,269.35%	-375.94%	-153.57%	-120.79%	-170.48%	-215.85%	-273.90%
Income Tax Expense	8.97M	58.00K	-1.33M	-2.44M	-722.00K	-1.26M	-678.00K	20.00K	390.00K	360.00K	500.00K	-416.00K	331.00K	-1.35M	-7.58M	-37.00K	32.00K	-1.08M	-1.12M	-2.29M	-3.44M	-2.84M	-3.53M	-1.59M	-701.00K
Net Income	-18.75M	-33.69M	-32.87M	-27.26M	-27.34M	-22.60M	-37.07M	-31.51M	-20.16M	-11.09M	-14.08M	-13.63M	-12.00M	-7.20M	-3.83M	-12.53M	-12.11M	-13.02M	-13.98M	-13.72M	-11.44M	-12.20M	-15.14M	-13.40M	-8.13M
Net Income Ratio	-56.05%	-449.25%	-547.88%	-1,363.00%	0.00%	-126.96%	0.00%	-4,425.00%	-217.34%	-89.71%	-396.82%	-5,631.40%	2,831.13%	-646.01%	-1,532.40%	-3,706.21%	-6,730.00%	-6,055.81%	-2,163.78%	-340.75%	-129.64%	-109.98%	-133.31%	-194.51%	-251.13%
EPS	-0.21	-0.39	-0.39	-0.34	-0.43	-0.41	-0.72	-0.62	-0.40	-0.23	-0.36	-0.38	-0.35	-0.22	-0.13	-0.44	-0.43	-0.47	-0.50	-0.50	-0.43	-0.47	-0.58	-0.96	-0.58
EPS Diluted	-0.21	-0.39	-0.39	-0.34	-0.43	-0.41	-0.72	-0.62	-0.40	-0.23	-0.36	-0.38	-0.35	-0.22	-0.13	-0.44	-0.43	-0.47	-0.50	-0.50	-0.43	-0.47	-0.58	-0.96	-0.58
Weighted Avg Shares Out	87.63M	86.56M	84.20M	79.59M	63.64M	55.28M	51.18M	50.86M	50.44M	47.81M	38.87M	35.84M	34.28M	33.28M	28.61M	28.43M	28.27M	27.99M	27.77M	27.47M	26.41M	26.10M	26.01M	13.91M	14.10M
Weighted Avg Shares Out (Dil)	87.63M	86.56M	84.20M	79.59M	63.64M	55.28M	51.18M	50.86M	50.44M	48.39M	38.87M	36.25M	34.28M	33.28M	28.61M	28.43M	28.27M	27.99M	27.77M	27.47M	26.41M	26.10M	26.01M	13.91M	14.10M

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

February 14, 2023prnewswire.com

Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 2023. AstraZeneca continues to expand rilvegostomig's Phase 2 development across multiple indications and combinations COM902, Compugen's potential best in class high affinity...

Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

February 13, 2023prnewswire.com

HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on...

Why Compugen Stock Got Slammed Today

February 8, 2023fool.com

Clinical-stage biotechs are particularly susceptible to shifts in analyst sentiment.

Why Shares of Compugen Rose on Thursday

December 29, 2022fool.com

The clinical-stage biotech retreated a bit from one of its biggest days in a while.

Why Shares of Compugen Rose 16.5% on Wednesday

November 30, 2022fool.com

Market factors and a company announcement helped the stock climb.

Why Shares of Compugen Jumped 17.86% on Thursday

November 17, 2022fool.com

The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.

4 Cheap Penny Stocks To Buy For Under $1 Right Now

November 17, 2022pennystocks.com

Penny stocks under $1 to watch before next week. The post 4 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Compugen Ltd. (CGEN) Q3 2022 Earnings Call Transcript

November 15, 2022seekingalpha.com

Compugen Ltd. (NASDAQ:CGEN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Yvonne Naughton - Head, Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Henry Adewoye - Chief Medical Officer...